Sleep Apnea
Conditions
Keywords
sleep apnea syndrome, CPAP, prostanoids
Brief summary
The purpose of this study is to evaluate the relationships between prostanoids and various outcomes such as sleep disturbance, hypertension and arteriosclerosis in patients with sleep apnea syndrome(SAS). In the patients introduced to continuous positive airway pressure(CPAP) treatment, the effects of CPAP are also evaluated.
Detailed description
SAS is characterized by abnormality during sleep and hypoxemia from apnea and hypopnea, followed by systemic inflammation and organ dysfunction like cardiovascular diseases. Systemic inflammation causes the activation of arachidonic acid metabolism, producing prostaglandins (PGs) and leukotrienes (LTs). In addition, significant relationships between PGD2 and PGE2 and sleep, PGF2α and hypertension, PGI2 and thromboxane and platelet aggregation and so on are reported. Therefore, it is hypothesized that many prostanoids affect the pathophysiology of SAS. However, the relationships between prostanoids and clinical outcomes in patients with SAS are unknown. Although CPAP is the major treatment of SAS, the effects of CPAP on prostanoids are not known, either. Thus, the purpose of this study is to evaluate those relationships.
Interventions
DEVICECPAP treatment
CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
Sponsors
Kyoto University, Graduate School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects hospitalized in Kyoto University Hospital for careful examination of SAS
Exclusion criteria
* Subjects with severe respiratory diseases, severe heart diseases, severe vascular diseases, or severe diabetes mellitus. * Subjects taking nonsteroidal anti-inflammatory drugs, steroids or immunosuppressants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| metabolites of arachidonic acid in the urine and blood | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Sleepiness and health-related quality of life | 3 months |
| Blood pressure and pulse rate | 3 months |
| Polysomnography measurements | 3 months |
| Platelet aggregation | 3 months |
| Cardiac and neck echo cardiography | 3 months |
| Endothelial dysfunction | 3 months |
Countries
Japan
Outcome results
None listed